Evidence for Follicle-stimulating Hormone Receptor as a Functional Trimer
Follicle-stimulating hormone receptor (FSHR), a G-protein coupled receptor, is an important drug target in the development of novel therapeutics for reproductive indications. The FSHR extracellular domains were observed in the crystal structure as a trimer, which enabled us to propose a novel model...
Gespeichert in:
Veröffentlicht in: | J. Biol. Chem 2014-05, Vol.289 (20), p.14273-14282 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Follicle-stimulating hormone receptor (FSHR), a G-protein coupled receptor, is an important drug target in the development of novel therapeutics for reproductive indications. The FSHR extracellular domains were observed in the crystal structure as a trimer, which enabled us to propose a novel model for the receptor activation mechanism. The model predicts that FSHR binds Asnα52-deglycosylated FSH at a 3-fold higher capacity than fully glycosylated FSH. It also predicts that, upon dissociation of the FSHR trimer into monomers, the binding of glycosylated FSH, but not deglycosylated FSH, would increase 3-fold, and that the dissociated monomers would in turn enhance FSHR binding and signaling activities by 3-fold. This study presents evidence confirming these predictions and provides crystallographic and mutagenesis data supporting the proposed model. The model also provides a mechanistic explanation to the agonist and antagonist activities of thyroid-stimulating hormone receptor autoantibodies. We conclude that FSHR exists as a functional trimer.
A carbohydrate of follicle-stimulating hormone (FSH) has been proposed to sterically block other FSH molecules from binding to the putative receptor (FSHR) trimer.
FSH increases its receptor binding by 3-fold when the steric hindrance is removed.
FSHR forms a functional trimer.
This knowledge may improve designs of therapeutic drugs targeting FSHR. |
---|---|
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M114.549592 |